Lantus Solostar solution for injections 100 IU/ml. 3 ml. №5 cartridge

Description

Lantus Solostar Composition

1 ml of solution contains:

active substance: insulin glargine

100 IU (3.6378 mg)

excipients: metacresol (m-cresol), zinc chloride, glycerol (85%), sodium hydroxide, hydrochloric acid, water for injection.

Lantus Solostar Description:

clear, colorless or almost colorless liquid.

Pharmacotherapeutic group:

long-acting hypoglycemic insulin analog

ATX code: A10AE04.

Lantus Solostar Pharmacological properties

Pharmacodynamics

Insulin glargine is an analogue of human insulin, obtained by recombination of DNA from bacteria of the species Escherichia coli (K12 strains).

Connection with insulin receptors: the kinetics of binding to specific insulin receptors in insulin glargine is very similar to that of human insulin, and therefore insulin glargine is capable of performing a biological effect similar to that of endogenous insulin.

The most important action of insulin and its analogs, including insulin glargine, is the regulation of glucose metabolism. Insulin and its analogs reduce blood glucose by stimulating glucose uptake by peripheral tissues (especially skeletal muscle and adipose tissue) and inhibiting the formation of glucose in the liver.

Insulin suppresses lipolysis in adipocytes and inhibits proteolysis, while simultaneously increasing protein synthesis.

The prolonged action of insulin glargine is directly related to the reduced rate of its absorption, which allows the drug to be used once a day. After subcutaneous administration, the onset of its action occurs, on average, after 1 hour. The average duration of action is 24 hours, the maximum is 29 hours. The duration of action of insulin and its analogs such as insulin glargine can vary significantly between individuals or within the same individual.

Pharmacokinetics

A comparative study of the serum concentrations of insulin glargine and insulin-isophane in healthy people and patients with diabetes mellitus after subcutaneous administration of the drugs revealed a slower and much longer absorption, as well as the absence of a peak in the concentration of insulin glargine in comparison with insulin-isophane.

With a single subcutaneous injection of the drug Lantus SoloStar during the day, the equilibrium concentration of insulin glargine in the blood is achieved after 2-4 days of daily administration.

When administered intravenously, the half-lives of insulin glargine and human insulin were comparable.

In humans, insulin glargine is partially cleaved in the subcutaneous fatty tissue from the carboxyl end (C-end) of the p-chain (beta-chain) to form 21 A-Gly-insulin and 21A-Gly-des-30B-Thr-insulin. Plasma contains both unchanged insulin glargine and its cleavage products.

Indications

Diabetes mellitus requiring insulin treatment in adults, adolescents and children over 6 years of age.

Lantus Solostar Contraindications

Carefully

Pregnant women (possibility of changing insulin requirements during pregnancy and after childbirth)